MedTrace Logo

Effect of Fingolimod on the Cardiac Autonomic Regulation in Patients With Multiple Sclerosis

NCT01704183 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 27

Last updated 2014-05-08

No results posted yet for this study

Summary

The purpose of this study is to study the effect of fingolimod on cardiac autonomic regulation in patients with relapse-remitting multiple sclerosis.

This will be done by measuring heart rate variability from the 24-hour Holter recording and myocardial ventricular repolarisation patterns from the 12-lead electrocardiogram tracings.

The fingolimod treatment is prescribed according to the accepted drug label.

Conditions

  • Relapse-remitting Multiple Sclerosis

Sponsors & Collaborators

  • Kuopio University Hospital

    lead OTHER

Principal Investigators

  • Sakari Simula, MD, PhD · Mikkeli Central Hospital, Department of Neurology

  • Päivi Hartikainen, MD, PhD · Kuopio University Hospital, Neuro Center

  • Juha Hartikainen, MD, PhD · Kuopio University Hospital, Heart Center

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • Finland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01704183 on ClinicalTrials.gov